Vertex Pharmaceuticals Incorporated
VRTX
$434.02
$4.421.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.21% | 5.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.87% | 5.05% | |||
| Cost of Revenue | 6.81% | -0.90% | |||
| Gross Profit | -13.74% | 10.08% | |||
| SG&A Expenses | 14.90% | -7.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.55% | -2.33% | |||
| Operating Income | -21.28% | 15.76% | |||
| Income Before Tax | -35.73% | -7.16% | |||
| Income Tax Expenses | -62.37% | 25.07% | |||
| Earnings from Continuing Operations | -29.21% | -12.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.21% | -12.67% | |||
| EBIT | -21.28% | 15.76% | |||
| EBITDA | -18.91% | 12.36% | |||
| EPS Basic | -29.04% | -12.50% | |||
| Normalized Basic EPS | -18.92% | 14.84% | |||
| EPS Diluted | -28.84% | -12.74% | |||
| Normalized Diluted EPS | -18.80% | 14.83% | |||
| Average Basic Shares Outstanding | -0.23% | -0.19% | |||
| Average Diluted Shares Outstanding | -0.38% | -0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||